Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

NIH 2NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Lymphoma, Large B-Cell, Diffuse 35Burkitt Lymphoma 33Lymphoma 26Lymphoma, Follicular 16Rhabdomyosarcoma 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, B-Cell 12Neuroblastoma 10Medulloblastoma 10Lymphoma, Non-Hodgkin 10Leukemia 10Sarcoma, Ewing 9Leukemia, Biphenotypic, Acute 9Recurrence 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Lymphoma, T-Cell, Peripheral 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Hodgkin Disease 7Sarcoma 5Retinoblastoma 5Wilms Tumor 4Osteosarcoma 4Lymphoproliferative Disorders 4Lymphoma, T-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Ganglioneuroblastoma 4Down Syndrome 4

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 7dinutuximab 6Topotecan 5Isotretinoin 5Doxorubicin 5Biopsy 5sargramostim 4Vincristine 4Stem Cell Transplantation 4Specimen Handling 4Radiation 4Platinum 4Melphalan 4Colony-Stimulating Factors 4Cisplatin 4Carboplatin 41,2-diaminocyclohexaneplatinum II citrate 4Thiotepa 3Temozolomide 3Irinotecan 3Etoposide 3Congresses as Topic 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2Busulfan 2lorlatinib 1iberdomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × Vincristine × 1 year × Clear all
NCT06172296 2026-05-27

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-04-13

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT01175356 2026-01-23

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Children's Oncology Group

Phase 1 Completed
99 enrolled 11 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡